Epigral Ltd (EPIGRAL) AI Stock Analysis

• Market Cap: ₹72.54B
• Dividend Yield: 0.36%
• Average Volume (3M): 1.86K
• Price to Earnings (P/E): 16.6
• Beta (1Y): 1.41
• Revenue Growth: 17.88%
• EPS Growth: 68.05%
• Country: IN
• Employees: 997
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals
• EPS (TTM): 18.50
• Shares Outstanding: 43,141,340
• 10 Day Avg. Volume: 1,295
• 30 Day Avg. Volume: 1,859
• PEG Ratio: 0.28
• Price to Book (P/B): 4.21
• Price to Sales (P/S): 3.14
• P/FCF Ratio: 32.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹1,751.00 ▲(5.99% Upside)

Epigral Ltd's strong financial performance is a key strength, supported by robust revenue growth and efficient operations. However, bearish technical indicators and a fair valuation with low dividend yield present challenges. The absence of earnings call data and corporate events limits additional insights.

Epigral Ltd Business Overview & Revenue Model

Company Description

Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.

How the Company Makes Money

Epigral Ltd generates revenue primarily through the sale of its proprietary drug delivery systems and regenerative medicine products. The company has established key partnerships with pharmaceutical firms for collaborative research and development, allowing it to leverage shared resources and expertise in bringing new products to market. Additionally, Epigral may earn income through licensing agreements for its technologies, enabling other companies to utilize its innovations in their own product lines. Grants and funding from government or private research organizations also contribute to the company's financial resources, supporting ongoing R&D efforts.

Epigral Ltd Financial Statement Overview

Summary

Epigral Ltd exhibits strong financial health with robust revenue growth, efficient operations, and improved cash flow management. The balance sheet reflects a solid equity position, though high debt levels warrant attention.

Income Statement

Epigral Ltd has demonstrated strong revenue growth with a significant increase from 2024 to 2025. The gross profit margin is robust, and the net profit margin has improved, reflecting effective cost management. EBIT and EBITDA margins are healthy, indicating operational efficiency. However, the volatility in revenue growth over the years suggests potential market risks.

Balance Sheet

The company's balance sheet shows a strong equity base with a favorable equity ratio. The debt-to-equity ratio has improved, indicating reduced financial leverage. Return on equity is solid, reflecting effective use of shareholders' funds. However, the total debt level remains substantial, which could pose risks if not managed carefully.

Cash Flow

Epigral Ltd has shown impressive free cash flow growth, turning negative free cash flow in 2024 into positive in 2025. The operating cash flow to net income ratio is strong, indicating good cash generation from operations. The free cash flow to net income ratio also reflects improved cash efficiency. However, fluctuations in capital expenditures highlight potential investment volatility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	25.05B	25.50B	18.94B	21.69B	15.50B	8.26B
Gross Profit	11.55B	10.67B	7.79B	6.43B	7.48B	4.13B
EBITDA	7.12B	7.11B	4.77B	6.81B	5.01B	2.66B
Net Income	4.33B	3.58B	1.96B	3.53B	2.53B	1.01B
Balance Sheet
Total Assets	0.00	31.52B	27.94B	24.32B	21.24B	14.49B
Cash, Cash Equivalents and Short-Term Investments	952.40M	965.00M	31.83M	142.40M	250.85M	6.80M
Total Debt	0.00	5.93B	9.64B	8.79B	9.93B	5.42B
Total Liabilities	-19.05B	12.48B	15.40B	13.63B	13.98B	7.65B
Stockholders Equity	19.05B	19.05B	12.54B	10.69B	7.26B	6.84B
Cash Flow
Free Cash Flow	0.00	2.46B	-7.90M	2.10B	-1.72B	324.17M
Operating Cash Flow	0.00	4.41B	3.98B	6.26B	2.84B	2.29B
Investing Cash Flow	0.00	-2.62B	-4.01B	-4.37B	-4.55B	-1.97B
Financing Cash Flow	0.00	-1.64B	-75.98M	-2.00B	1.95B	-319.00M

Epigral Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1652.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Negative. The current price of 1652.1 is below the 20-day moving average (MA) of 1693.12, below the 50-day MA of 1732.15, and below the 200-day MA of 1794.54, indicating a bearish trend. The MACD of -16.64 indicates Positive momentum. The RSI at 34.51 is Neutral, neither overbought nor oversold. The STOCH value of 21.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:EPIGRAL.

Epigral Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	75 Outperform	₹62.69B	35.20	―	0.13%	13.68%	31.69%
MARKSANS	70 Neutral	₹82.82B	23.65	―	0.44%	16.94%	4.90%
STAR	69 Neutral	₹88.71B	22.32	―	0.42%	6.22%	123.83%
EPIGRAL	62 Neutral	₹72.54B	16.61	―	0.36%	17.88%	68.05%
GUFICBIO	57 Neutral	₹32.77B	52.96	―	0.03%	2.37%	-30.78%
SHILPAMED	54 Neutral	₹70.06B	63.07	―	0.14%	11.13%	127.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Epigral Ltd Corporate Events

Epigral Limited Schedules Q2 FY26 Results Conference Call

Epigral Limited has announced a conference call scheduled for November 10, 2025, to discuss its Q2 FY26 financial results. This call will feature key company executives and is organized in compliance with SEBI regulations. The announcement is significant for stakeholders as it provides an opportunity to gain insights into the company’s financial performance and strategic direction.

Epigral Limited Confirms Compliance with SEBI Regulations for Q3 2025

Epigral Limited has submitted a confirmation certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. The certificate, provided by MUFG Intime India Private Limited, confirms that securities received for dematerialization during the quarter were processed and listed on the stock exchanges, ensuring compliance with regulatory requirements.